- Home
- ADPT vs MDXG Comparison
ADPT vs MDXG Comparison
Compare ADPT & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- MDXG
- Stock Information
- Founded
- ADPT 2009
- MDXG 2006
- Country
- ADPT United States
- MDXG United States
- Employees
- ADPT N/A
- MDXG N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- MDXG Health Care
- Exchange
- ADPT Nasdaq
- MDXG Nasdaq
- Market Cap
- ADPT 1.1B
- MDXG 1.2B
- IPO Year
- ADPT 2019
- MDXG N/A
- Fundamental
- Price
- ADPT $7.43
- MDXG $7.60
- Analyst Decision
- ADPT Strong Buy
- MDXG Strong Buy
- Analyst Count
- ADPT 5
- MDXG 3
- Target Price
- ADPT $9.40
- MDXG $12.00
- AVG Volume (30 Days)
- ADPT 2.2M
- MDXG 535.9K
- Earning Date
- ADPT 05-06-2025
- MDXG 04-29-2025
- Dividend Yield
- ADPT N/A
- MDXG N/A
- EPS Growth
- ADPT N/A
- MDXG N/A
- EPS
- ADPT N/A
- MDXG 0.28
- Revenue
- ADPT $178,957,000.00
- MDXG $348,879,000.00
- Revenue This Year
- ADPT $21.21
- MDXG $10.09
- Revenue Next Year
- ADPT $21.98
- MDXG $11.77
- P/E Ratio
- ADPT N/A
- MDXG $26.93
- Revenue Growth
- ADPT 5.10
- MDXG 8.52
- 52 Week Low
- ADPT $2.28
- MDXG $5.47
- 52 Week High
- ADPT $9.01
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- ADPT 44.19
- MDXG 38.98
- Support Level
- ADPT $6.92
- MDXG $7.84
- Resistance Level
- ADPT $9.01
- MDXG $8.12
- Average True Range (ATR)
- ADPT 0.57
- MDXG 0.24
- MACD
- ADPT -0.01
- MDXG -0.02
- Stochastic Oscillator
- ADPT 24.58
- MDXG 24.05
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.